March 7 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said it has received a warning letter from the U.S. Food and Drug Administration following inspections of its two key ...

My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 earnings release conference call. All lines ...

DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue ...

Financial giants have made a conspicuous bearish move on DexCom. Our analysis of options history for DexCom DXCM revealed 12 unusual trades. Delving into the details, we found 33% of traders were ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

DexCom DXCM0.71%increase; green up pointing triangle received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is ...

DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is working on a written response. The diabetes devices ...

2025 Adjusted EBITDA Guidance: Approximately 30%. DexCom Inc (NASDAQ:DXCM) reported an 8% organic revenue growth in Q4 2024, aligning with their guidance. The company expanded its global customer ...

Here’s how it works. After the LG G5’s reveal at CES 2025, one of the headline announcements – and what I described as its most anticipated upgrade – was a big claimed boost in its ...

In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against the other IoT stocks. According to the IOT analytics, 2024 was a poor year for the Internet of ...